Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline for Epistaxis in HHT
NCT03397004Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Sep 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of doxycycline in hereditary hemorrhagic telangiectasia (HHT), sponsored by Unity Health Toronto. Started Sep 2018; status: completed.
02
Drugs
doxycycline
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT03397004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397004.